Eli Lilly And Co vs PayPal Holdings, Inc. — how do they compare? Eli Lilly And Co trades at $1,172.88 (market cap $1.02T), while PayPal Holdings, Inc. trades at $55.86 (market cap $50.12B). The key difference: Eli Lilly And Co is far larger — about 20.4× PayPal Holdings, Inc.'s market cap, and PayPal Holdings, Inc. pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| LLY | PYPL | |
|---|---|---|
Market Cap | $1.02T | $50.12B |
Sector | Health | Financials |
52-Week High | $1.24K | $78.22 |
52-Week Low | $625.65 | $39.08 |
Enterprise Value | $1.06T | $50.19B |
Dividend Yield | 0.6% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
PayPal (PYPL) trades at $55.85, down 1.26% today, amid takeover speculation from Stripe and Advent International. The stock shows strong fundamentals with a P/E of 10.66 and net income margin of 15%, while technical indicators are mixed with a bullish moving average signal but overbought RSI levels. Recent earnings beat expectations in Q1 2026, and the company maintains robust cash flow from operations of $6.42 billion in 2025.
The outlook is clouded by the potential buyout, which could limit upside if the offer is rejected, while profitability pressures and competition from Apple Pay pose risks. Analyst consensus is cautious with a hold-heavy rating, suggesting investors await clarity on strategic direction amid the takeover bid.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →